Diabetic nephropathy (DN) is a serious complication of diabetes mellitus characterized by renal dysfunction and structural abnormalities. This study induced diabetes in rats using streptozotocin (STZ) and explored the therapeutic effects of resveratrol and naringin, natural compounds known for their antioxidant and anti-inflammatory properties. The combination treatment of resveratrol and naringin significantly lowered serum glucose levels compared to diabetic controls. Resveratrol demonstrated renal protective effects by reducing inflammation and oxidative stress, while naringin enhanced insulin sensitivity and shielded beta cells from oxidative damage. Resveratrol and naringin also mitigated dyslipidemia, a common issue in diabetic nephropathy, by adjusting lipid metabolism markers. Markers of renal function, including serum creatinine, albumin, total protein, and blood urea nitrogen (BUN), were examined to assess treatment effectiveness. Resveratrol decreased urinary total protein levels, alleviated albuminuria, and enhanced renal function markers. Naringin contributed protective effects through antioxidant mechanisms and modulation of renal injury biomarkers. Both compounds exhibited potent antioxidant activities by increasing glutathione (GSH) levels and decreasing lipid peroxidation. They additionally suppressed inflammatory cytokines such as TNF-α and IL-6, thereby reducing inflammation and preserving renal function. In conclusion, the combined therapy of resveratrol and naringin synergistically improved diabetic nephropathy by targeting multiple pathways involved in hyperglycemia, dyslipidemia, oxidative stress, and inflammation. These findings highlight the therapeutic potential of resveratrol and naringin in managing diabetic complications, emphasizing their comprehensive approach to preserving renal function.